- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical ...
Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal ...
NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the ...
A diagnosis of amyotrophic lateral sclerosis can be overlooked by clinicians unfamiliar with the various signs of the disease. ALS is purely a motor neuron disease; sensory neurons are not affected. 4 ...
—The effort required to manage a patient’s physical manifestations of ALS often overshadows the disease’s psychological burdens. That’s changing. Reviewed by Aaron Miller, MD, Professor of Neurology, ...
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback